Sherry Aulin - Jun 3, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Financial Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Jun 3, 2021
Transactions value $
$0
Form type
4
Date filed
6/3/2021, 04:42 PM
Next filing
Mar 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +100K $0.00 100K Jun 3, 2021 Common Shares 100K $18.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.